Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change ...

Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S.

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an ...

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Both companies may succeed in this industry.

In this photo illustration, a Eli Lilly logo seen displayed on a smartphone. Eli Lilly’s stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...